A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the body after treatment.

Trial Details

NCT ID
NCT06347705
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 2141-V11 Antibody
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Willing and able to provide written informed consent and Authorization for Use and Release of Health and Research Study Information (HIPAA authoriz…
  • Male aged 18 years and above
  • Serum testosterone of ≥150 ng/dL except for patients currently on ADT.
  • Adequate bone marrow, hepatic, and renal function, as evidenced within 28 days prior to treatment start by:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →